ClinicalTrials.gg
CompletedNCT02547818COGNITEUpdated Nov 10, 2021

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

A Phase 3 interventional study of ALZT-OP1a and ALZT-OP1b in Alzheimer's Disease, sponsored by AZTherapies, Inc.. Completed at 121 sites in 7 countries. Open to participants aged 55 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-11-10.

Sponsored by AZTherapies, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
55 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
146th of 1,609
620 · median 73
Started
2015
with 71 others
Phase 3
188 of 1,940
19 open now
Registered
733rd of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 146th largest by enrollment of the 1,609 interventional ones that give a count, is one of 72 that started in 2015, is one of 188 in phase 3, and was the 733rd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subjects with evidence of early stage Alzheimer's disease (AD).

Read the detailed description

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in an early stage AD population.

Subjects will be randomly assigned to one of four treatment arms: Group I will consist of ALZT-OP1a (cromolyn) for inhalation, plus an oral placebo tablet; OR the Group II arm, which will consist of ALZT-OP1 combination therapy ALZT-OP1a (cromolyn) for inhalation, plus ALZT-OP1b (ibuprofen) tablet for oral administration; OR to the Group III arm, which will consist of inhaled placebo, plus ALZT-OP1b (ibuprofen) tablet for oral administration; OR to the Group IV placebo arm, which will consist of inhaled placebo plus an oral placebo tablet.

A minimum of 400 evaluable subjects will be randomized to receive one of four possible treatment assignments containing various combinations of active study drug or placebo.

To account for subject dropouts (estimated rate of 30%), it is anticipated that up to 600 (or 150 subjects per treatment arm) may be recruited and randomized, to achieve a minimum of 100 evaluable subjects per treatment arm.

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Early stage AD
  • MCI
  • aMCI
  • prodromal
  • Memory loss
  • Memory problems
  • Aging
  • Early Alzheimer's Disease
  • Early AD
04

Who can participate

Ages eligible
55 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 55-79 years old;
  • ≥ 8 years of education;
  • Study partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to all clinic visits for the duration of the protocol;
  • Evidence of early AD, as defined by all of the following:

    1. Memory complaint by subject or study partner that is verified by a study partner;
    2. Objective memory impairment for age, documented by scoring below the education adjusted cutoff of the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale Third Edition (the maximum score is 25):

      • ≤ 8 for 16 or more years of education, or
      • ≤ 4 for 8-15 years of education;
      • Essentially preserved general cognitive function;
      • Largely intact functional activities;
      • Not demented;
  • Cerebrospinal fluid (CSF) biomarker results consistent with early AD, including CSF Aβ-42 levels ≥ 180 pg/mL and ≤ 690 pg/mL;
  • Clinical Dementia Rating (Global) = 0.5; Memory Box score must be at least 0.5;
  • Must be fluent in the language of the cognitive testing material being administered;
  • Stability of permitted medications for 4 weeks prior to study start; subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those medications for at least 12 weeks prior to study start with every effort to maintain stable dose for the duration of the study;
  • Visual and auditory acuity adequate for neuropsychological testing;
  • Good general health with no diseases expected to interfere with the study;
  • Must provide written for APOe4 genotype testing;
  • Must provide written informed consent for CSF sampling.

Exclusion criteria

Exclusion Criteria:

  • Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities;
  • Major depressive episode, as described in the (DSM-IV) within the past 6 months, which could lead to difficulty complying with the protocol;
  • History of schizophrenia or bipolar disorder (DSM-IV criteria);
  • History of alcohol or substance abuse or dependence within the past 3 years (DSM-IV criteria);
  • Currently taking medications that could lead to difficulty complying with the protocol; subjects must be on a stable dose of current medications for 4 weeks prior to study entry, with the exception of acetylcholinesterase inhibitors and/or memantine, which must be on a stable dose for at least 12 weeks prior to study entry;
  • agents are prohibited one month prior to entry and for the duration of the trial;
  • Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin);
  • Currently taking cromolyn, or have taken cromolyn, within the past 12 months;
  • Chronic daily use of high-dose NSAID for osteoarthritis, rheumatoid arthritis, or other chronic inflammatory diseases ("chronic" defined as 3200 mg/day for >2 weeks);
  • Chronic daily use of aspirin exceeding standard of care guidelines for low dose aspirin therapy for prevention of stroke and/or other recommended uses;
  • Allergy to cromolyn (also known as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.);
  • Allergies to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin;
  • respiratory disorders with impaired respiratory effort or difficulty taking inhaled drugs;
  • Uncontrolled chronic asthma;
  • Abnormal pulmonary function test, defined for this protocol as: /FVC \< predicted value for subject AND FEV1 \< 70% of predicted value, indicating moderate or severe respiratory obstruction;
  • Taking inhaled protein products on a chronic basis;
  • Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol;
  • Pregnancy or lactation for female subjects of (i.e., \< two years or not surgically sterile);
  • For sexually active male subjects, unwillingness or incapability of using appropriate methods;
  • Severe renal or hepatic impairment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
620 participants (actual)

Study arms

  • Active comparator
    Group I

    ALZT-OP1a active capsules for inhalation and ALZT-OP1b placebo capsules for oral administration.

    Drug: ALZT-OP1a · Other: Placebo ALZT-OP1b

  • Active comparator
    Group II

    ALZT-OP1a active capsules for inhalation and ALZT-OP1b active tablets for oral administration.

    Drug: ALZT-OP1a · Drug: ALZT-OP1b

  • Active comparator
    Group III

    ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b active tablets for oral administration.

    Drug: ALZT-OP1b · Other: Placebo ALZT-OP1a

  • Placebo comparator
    Group IV

    ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b placebo tablets for oral administration.

    Other: Placebo ALZT-OP1a · Other: Placebo ALZT-OP1b

Interventions

  • 1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory

    Also known as: Cromolyn

  • Anti-inflammatory

    Also known as: Ibuprofen

  • OtherPlacebo ALZT-OP1a

    Non-active capsules

  • OtherPlacebo ALZT-OP1b

    Non-active tablets

06

What researchers measure

Primary outcomes

  1. Clinical Dementia Rating-Sum of Boxes (CDR-SB)

    The combination active treatment group will be compared to each of the single component groups, including the placebo group, the mean change from Baseline to Week 72 will be quantified.

    Time frame: Baseline and Week 72

Secondary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAE)

    Safety will be evaluated based on the number, type, and frequency of treatment emergent adverse events. They will be individually presented for all subjects in data listings, and summarized in tables by treatment group and by treatment assignment. The AE's will be summarized and reported collectively based on information obtained through physical examination, ECG, and laboratory findings captured after dosing is initiated.

    Time frame: 72 weeks

07

Study locations

121 sites
  • Cognitive Clinical Trials
    Gilbert, Arizona 85296, United States
  • Xenoscience
    Phoenix, Arizona 85004, United States
  • Cognitive Clinical Trials
    Scottsdale, Arizona 85251, United States
  • Territory Neurology & Research Institute
    Tucson, Arizona 85704, United States
  • Alliance Research Center
    Laguna Hills, California 92653, United States
  • Renew Behavioral Health
    Long Beach, California 90807, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • University of California Irvine School of Medicine
    Orange, California 92868, United States
  • Asclepes Research Center
    Panorama City, California 91402, United States
  • Artemis Clinical Research
    Riverside, California 92503, United States
  • CITrials
    Riverside, California 92506, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Syrentys Clinical Research
    Santa Ana, California 92705, United States
  • Mile High Research Center
    Denver, Colorado 80218, United States
  • TOPAZ Clinical Research
    Apopka, Florida 32703, United States
  • Parkinson's Disease & Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • Bradenton Research Center
    Bradenton, Florida 34205, United States
  • Finlay Medical Research Group
    Greenacres City, Florida 33467, United States
  • Galiz Clinical Research
    Hialeah, Florida 33016, United States
  • Panax
    Miami Lakes, Florida 33014, United States
  • The Neurology Research Group
    Miami, Florida 22176, United States
  • Premier Clinical Research Institute
    Miami, Florida 33122, United States
  • Finlay Medical Research Group
    Miami, Florida 33126, United States
  • Next Phase Research Alliance - Cano Health
    Miami, Florida 33144, United States
  • IMIC, Inc.
    Miami, Florida 33157, United States
  • Next Phase Research Alliance - MetroMed
    Miami, Florida 33186, United States
  • Next Phase Research Alliance
    Miami, Florida 33186, United States
  • CNS Healthcare
    Orlando, Florida 32801, United States
  • Pines Care Research Center
    Pembroke Pines, Florida 33026, United States
  • Neurostudies, Inc.
    Port Charlotte, Florida 33952, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Axiom Clinical Research
    Tampa, Florida 33609, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Columbus Research & Wellness Institute
    Columbus, Georgia 31904, United States
  • Behavioral Health Care Associates
    Schaumburg, Illinois 60193, United States
  • Eastern Maine Medical Center
    Bangor, Maine 04401, United States
  • Coastal Health Care
    Freeport, Maine 04032, United States
  • Samuel and Alexia Bratton Memory Clinic
    Easton, Maryland 21601, United States
  • ActivMed Practices & Research, Inc.
    Methuen, Massachusetts 01844, United States
  • The Alzheimer's Disease Center
    Quincy, Massachusetts 02169, United States
  • Bronson Neurobehavioral Health
    Paw Paw, Michigan 49079, United States
  • Cognitive Clinical Trials
    Bellevue, Nebraska 68005, United States
  • Cognitive Clinical Trials
    Omaha, Nebraska 68007, United States
  • ActivMed Practices & Research Inc.
    Portsmouth, New Hampshire 03801, United States
  • Memory Enhancement Center of America
    Eatontown, New Jersey 07724, United States
  • AdvancedMed Research
    Lawrenceville, New Jersey 08648, United States
  • The NeuroCognitive Institute
    Mount Arlington, New Jersey 07856, United States
  • Albuquerque Neuroscience
    Albuquerque, New Mexico 87109, United States
  • Adirondack Medical Research Center
    Glens Falls, New York 12801, United States
  • Manhattan Behavioral Medicine
    New York, New York 10023, United States
  • Medical Research Network
    New York, New York 10128, United States
  • Nathan S. Kline Institute for Psychiatric Research
    New York, New York 10128, United States
  • Winifred Masterson Burke Medical Research Institute
    White Plains, New York 10605, United States
  • ANI Neurology, PLLC Alzheimer's Memory Center
    Charlotte, North Carolina 28270, United States
  • Raleigh Neurological Associates
    Raleigh, North Carolina 27607, United States
  • PMG Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Insight Clincial Trials
    Shaker Heights, Ohio 44122, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73116, United States
  • Tulsa Clinical Research, Inc.
    Tulsa, Oklahoma 74114, United States
  • Pearl Clinical Research
    Norristown, Pennsylvania 19401, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Palmetto Health
    Columbia, South Carolina 29044, United States
  • Metrolina Neurological Associates, PA
    Rock Hill, South Carolina 29732, United States
  • CNS Healthcare
    Memphis, Tennessee 38119, United States
  • Neurology Associates of Arlington, P.A.
    Mansfield, Texas 76063, United States
  • Grayline Clinical Drug Trials
    Wichita Falls, Texas 76309, United States
  • Wasatch Clinical Research, LLC
    Salt Lake City, Utah 84107, United States
  • Kingfisher Cooperative
    Spokane, Washington 99202, United States
  • St Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • KaRa Institute of Neurological Diseases
    Macquarie Park, New South Wales 2113, Australia
  • Pacific Private Clinic
    Southport, Queensland 4215, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Geelong Private Medical Centre
    Geelong, Victoria 3220, Australia
  • Austin Health
    Heidelberg, Victoria 3081, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • UMBAL "Dr. Georgi Stranski" EAD
    Pleven, 5800, Bulgaria
  • MHAT "Central Onco Hospital" Ltd.
    Plovdiv, 4000, Bulgaria
  • MBAL Ruse AD
    Ruse, 7002, Bulgaria
  • "First MHAT - Sofia" EAD
    Sofia, 1154, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Aleksandrovska" EAD
    Sofia, 1431, Bulgaria
  • Medical Arts Health Research
    Penticton, British Columbia V2A 5L5, Canada
  • Medical Arts Health Research
    West Vancouver, British Columbia V7T 1C5, Canada
  • Okanagan Clinical Trials
    Kelowna, Britsh Columbia V1Y 1Z9, Canada
  • Montreal Neurological Research Institute
    Québec, Montreal H3A 284, Canada
  • True North Clinical Research
    Halifax, Nova Scotia B3S 1M7, Canada
  • True North Clinical Research
    Kentville, Nova Scotia B4N 4K9, Canada
  • JBN Medical
    Burlington, Ontario L7M 4Y1, Canada
  • Chatham-Kent Clinical Trials
    Chatham, Ontario N7l1C1, Canada
  • The Centre for Memory and Aging
    East York, Ontario M4G 3E8, Canada
  • Cliniuqe de la Memoire de l'Outouais
    Gatineau, Quebec J8T 8J1, Canada
  • Neurosanatio, s.r.o.
    Litomyšl, Czech Republic 570 01, Czechia
  • Neurologie MU - Ondrej Koci, s.r.o.
    Novy Bor, Czech Republic 473 01, Czechia
  • CT Center MaVfe, s.r.o
    Olomouc, Czech Republic 779 00, Czechia
  • Vestra Clinics, s.r.o.
    Rychnov Nad Kněžnou, Czech Republic 516 01, Czechia
  • NEUROHK, s.r.o.
    Chocen, 565 01, Czechia
  • Clinline Services s.r.o.
    Hostivice, 253 01, Czechia
  • Psychiatricka ambulance
    Hradec Kralove, 503 41, Czechia
  • Psychiatricka ambulance Supervize s.r.o.
    Kutná Hora, 28401, Czechia
  • Krajska nemocnice Liberec a.s.
    Liberec, 460 63, Czechia

Showing the first 100 of 121 sites across 7 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Nov 2020, 61 months.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 61 months is above that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2015
First posted
Sep 11, 2015
StartActual
Sep 15, 2015
Primary completionActual
Nov 13, 2020
CompletionActual
Nov 18, 2020
Results delay requested
Nov 8, 2021
Last update
Nov 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02547818
Lead sponsor
AZTherapies, Inc.
Collaborators
PharmaConsulting Group, KCAS Bio, APCER Life Sciences
Responsible party
Sponsor
First posted
Sep 11, 2015
Start date
Sep 15, 2015
Primary completion
Nov 13, 2020
Completion
Nov 18, 2020
Last update
Nov 10, 2021

Study contacts

David R. Elmaleh, PhD
study director · AZTherapies, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cromolyn · Ibuprofen

Start the discussion